Comparative Pharmacology
Head-to-head clinical analysis: VALRELEASE versus VIMPAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VALRELEASE versus VIMPAT.
VALRELEASE vs VIMPAT
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Increases GABAergic transmission by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
Selective enhancement of slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.
Epilepsy (partial, generalized, absence seizures)Bipolar disorder (mania)Migraine prophylaxis (off-label)
Monotherapy or adjunctive therapy in the treatment of partial-onset seizures in patients 1 year of age and olderAdjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older
500 mg orally twice daily, extended-release formulation. Maximum dose: 2000 mg/day.
Adults: 200 mg oral or IV as a loading dose, followed by 100 mg twice daily (200 mg/day) starting the day after loading. May increase by 50 mg twice daily every week up to 200 mg twice daily (400 mg/day).
None Documented
None Documented
Terminal elimination half-life is 6-16 hours (mean 10.6 h) in adults; shorter at 4-12 h in children due to enhanced clearance; prolonged to 12-18 h in hepatic impairment or elderly. Clinical context: Once-daily dosing requires extended-release formulation (Valrelease) to maintain trough levels.
Terminal half-life: 13-16 hours (mean ~13 h at steady state); prolonged with renal impairment (CrCl <30 mL/min: ~22 h) and in patients with hepatic impairment (Child-Pugh B: ~17 h; Child-Pugh C: ~22 h).
Hepatic via glucuronidation and beta-oxidation; CYP450 not significantly involved.
Primarily via glucuronidation by UGT2B7, UGT1A8, UGT1A9, and UGT1A1; minor oxidation via CYP2C19 to O-desmethyl metabolite.
Renal: 70-80% as metabolites (valproic acid glucuronide, 3-oxo-valproate, 2-en-valproate) and <3% unchanged. Hepatic: 15-20% via bile into feces. Other: 1-3% exhaled as CO2.
Renal: ~95% (40% as parent drug, 39% as O-desmethyl metabolite, and ~15% as other minor metabolites); minimal biliary/fecal elimination (less than 1%).
88-92% bound, primarily to albumin. Binding is concentration-dependent and saturable at high levels (>100 mcg/mL), leading to increased free fraction.
<15% bound to serum proteins; binding is to albumin and alpha-1-acid glycoprotein.
0.13-0.23 L/kg (mean 0.16 L/kg) in adults; higher in neonates (0.3-0.4 L/kg). Clinical meaning: Low Vd reflects limited extravascular distribution, with higher concentrations in brain due to active transport.
0.45 L/kg (mean); distributes into total body water; higher Vd in children (0.6-0.7 L/kg).
Oral (extended-release): Approximately 100% relative to immediate-release valproic acid when adjusting for dose; slightly lower due to incomplete absorption (about 90% absorbed).
Oral immediate-release: ~100% (nearly complete absorption). Intravenous: 100% (bioequivalent to oral). Oral extended-release: ~100% (slightly lower Cmax but bioequivalent in AUC).
GFR 30-49 mL/min: 25% dose reduction; GFR 15-29 mL/min: 50% dose reduction; GFR <15 mL/min: avoid use.
CrCl ≥50 mL/min: usual dose. CrCl 30-49 mL/min: maximum 250 mg/day. CrCl 15-29 mL/min: maximum 200 mg/day. CrCl <15 mL/min: not recommended. Hemodialysis: maximum 250 mg/day; consider supplement after dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: maximum 300 mg/day. Child-Pugh B: maximum 200 mg/day. Child-Pugh C: not recommended.
For weight ≥25 kg: 20 mg/kg/day divided twice daily, maximum 1000 mg/day. Adjust based on therapeutic response.
1 month to <17 years: loading dose optional 3.5 mg/kg IV, then 1 mg/kg twice daily (2 mg/kg/day); may increase by 0.5 mg/kg twice daily every week to maintenance 3 mg/kg twice daily (6 mg/kg/day, max 200 mg twice daily).
Initiate at 250 mg twice daily; increase slowly due to decreased renal function and increased sensitivity.
Consider dose adjustment based on renal function; start at lower dose (e.g., 100 mg/day) if CrCl <50 mL/min. Monitor for adverse effects.
WARNING: TERATOGENICITY - VALRELEASE can cause fetal harm. Women of childbearing potential must use effective contraception.
None.
["Hepatotoxicity","Pancreatitis","Hyperammonemia","Teratogenicity","Somnolence","Thrombocytopenia"]
["Suicidal behavior and ideation","Dizziness and ataxia","Syncope and hypotension","Cardiac conduction abnormalities (PR prolongation, atrial fibrillation, atrial flutter)","Withdrawal seizures"]
["Hypersensitivity to valproate","Hepatic disease or significant dysfunction","Urea cycle disorders","Known mitochondrial disorders (e.g., POLG mutations)"]
["Hypersensitivity to lacosamide or any ingredient in the formulation"]
Data Pending Review
Data Pending Review
Grapefruit juice may increase diazepam levels; avoid concurrent use. High-fat meals may delay absorption but do not affect overall bioavailability. Alcohol potentiates CNS depression; strict avoidance recommended.
VIMPAT can be taken with or without food. No specific food interactions have been reported. Alcohol may increase central nervous system side effects (e.g., dizziness, drowsiness); avoid excessive alcohol consumption.
First trimester: Valproate is associated with a 3-5% risk of neural tube defects (e.g., spina bifida), as well as increased risks of orofacial clefts, cardiovascular malformations, and hypospadias. Second and third trimesters: Exposure may lead to neurodevelopmental deficits, including lower IQ and autism spectrum disorders. Fetal valproate syndrome (craniofacial abnormalities, limb defects) is documented.
VIMPAT (lacosamide) is classified as Pregnancy Category C. Animal studies have shown fetal harm at doses comparable to human therapeutic levels. In first trimester, there is a potential risk of major congenital malformations, though human data are limited. During second and third trimesters, there is risk of adverse neurodevelopmental outcomes and growth restriction. Use only if benefit outweighs risk.
Valproate is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.05-0.1, resulting in infant serum levels 1-10% of maternal levels. The American Academy of Pediatrics considers it compatible with breastfeeding; however, monitor infant for thrombocytopenia, hepatic dysfunction, and sedation.
Lacosamide is excreted in human milk. The milk-to-plasma ratio (M/P) is 0.4-0.6. Infant exposure is estimated at 2-3% of maternal weight-adjusted dose. Monitor infant for somnolence, poor feeding, and growth. Caution recommended.
During pregnancy, valproate clearance increases by 20-50% due to enhanced renal elimination and plasma volume expansion. Total (concentration adjusted) valproate levels decrease, but free (active) fraction may increase. Monitor free valproate levels (target 4-12 mcg/mL) and adjust dose to maintain seizure control. Postpartum, decrease dose to pre-pregnancy levels within 2-4 weeks to avoid toxicity.
Pregnancy can decrease lacosamide concentrations due to increased clearance. Monitor serum levels and adjust dose as needed to maintain trough concentrations at pre-pregnancy therapeutic levels. Postpartum, reduce dose to pre-pregnancy levels to avoid toxicity.
Category C
Category C
Valrelease (diazepam extended-release) has a slower onset but prolonged duration compared to immediate-release diazepam. Avoid in narrow-angle glaucoma. Use with caution in hepatic impairment; adjust dose. Monitor for respiratory depression, especially with concurrent CNS depressants. Abrupt discontinuation may precipitate withdrawal seizures.
VIMPAT (lacosamide) is a third-generation antiepileptic drug that enhances slow inactivation of voltage-gated sodium channels. Dose reduction required in severe renal impairment (CrCl <30 mL/min) and hepatic impairment (Child-Pugh B or C). Anaphylaxis and angioedema reported; discontinue if occurs. May cause PR interval prolongation; caution with other drugs that prolong PR interval (e.g., beta-blockers, calcium channel blockers). Withdrawal should be gradual to avoid increased seizure frequency. IV formulation is bioequivalent to oral; can be used for loading in status epilepticus (200-400 mg IV over 15 min).
Do not crush or chew capsules; swallow whole with liquid.Avoid alcohol and other CNS depressants.May cause drowsiness or dizziness; avoid driving until effects are known.Do not stop abruptly; tapering is required to prevent withdrawal.Take exactly as prescribed; misuse can lead to dependence.Notify your doctor if you experience yellowing of eyes/skin, mood changes, or difficulty breathing.
Take exactly as prescribed; do not stop suddenly as this may increase seizures.Common side effects: dizziness, headache, nausea, double vision (diplopia), and coordination problems. These may improve with continued use.Avoid driving or operating heavy machinery until you know how VIMPAT affects you, as it may cause dizziness or blurred vision.Inform your doctor if you have kidney or liver disease, heart problems (especially heart block), or if you are pregnant or breastfeeding.VIMPAT may increase the risk of suicidal thoughts or behavior; monitor mood changes and contact doctor immediately.Swallow tablets whole; do not crush or chew. Oral solution should be measured with the provided dosing device.